Asterias Biotherapeutics Inc. | Mutual Funds
Mutual Funds that own Asterias Biotherapeutics Inc.
British & American Investment Trust Plc (Top 20 Holdings)
1,101,439
1.98%
300,481
4.49%
12/31/2017
Vanguard Total Stock Market Index Fund
804,565
1.45%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
326,770
0.59%
2,300
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
138,363
0.25%
0
0.05%
12/31/2017
Fidelity Spartan Extended Market Index Fund
102,523
0.19%
0
0%
07/31/2018
Thrivent Variable Product - Moderate Allocation Portfolio
99,141
0.18%
-23,819
0%
03/31/2018
iShares Micro Cap ETF
81,753
0.15%
0
0.01%
09/06/2018
CREF Stock Account
66,199
0.12%
0
0%
03/31/2018
Thrivent Variable Product - Moderately Aggressive Allo. Port.
62,433
0.11%
-7,720
0%
03/31/2018
Fidelity Spartan Small Cap Index Fund
59,606
0.11%
-316
0%
04/30/2018
| Address |
6300 Dumbarton Circle
Fremont California 94555
United States
|
|
Employees
|
- |
| Website |
http://www.asteriasbiotherapeutics.com |
| Updated |
09/14/2018 |
| Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. |
